دورية أكاديمية
Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity.
| العنوان: | Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity. |
|---|---|
| المؤلفون: | Golubic, Rajna, Kennet, Jane, Parker, Victoria, Robertson, Darren, Luo, Dan, Hansen, Lars, Jermutus, Lutz, Ambery, Phil, Ryaboshapkina, Maria, Surakala, Manasa, Laker, Rhianna C, Venables, Michelle, Koulman, Albert, Park, Adrian, Evans, Mark |
| بيانات النشر: | Wiley Department of Medicine Diabetes Obes Metab |
| سنة النشر: | 2024 |
| المجموعة: | Apollo - University of Cambridge Repository |
| مصطلحات موضوعية: | clinical trial, drug development, energy regulation, incretin physiology, weight control |
| الوصف: | AIMS: To establish which components of energy balance mediate the clinically significant weight loss demonstrated with use of cotadutide, a glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, in early-phase studies. MATERIALS AND METHODS: We conducted a phase 2a, single-centre, randomized, placebo-controlled trial in overweight and obese adults with type 2 diabetes. Following a 16-day single-blind placebo run-in, participants were randomized 2:1 to double-blind 42-day subcutaneous treatment with cotadutide (100-300 μg daily) or placebo. The primary outcome was percentage weight change. Secondary outcomes included change in energy intake (EI) and energy expenditure (EE). RESULTS: A total of 12 participants (63%) in the cotadutide group and seven (78%) in the placebo group completed the study. The mean (90% confidence interval [CI]) weight change was -4.0% (-4.9%, -3.1%) and -1.4% (-2.7%, -0.1%) for the cotadutide and placebo groups, respectively (p = 0.011). EI was lower with cotadutide versus placebo (-41.3% [-66.7, -15.9]; p = 0.011). Difference in EE (per kJ/kg lean body mass) for cotadutide versus placebo was 1.0% (90% CI -8.4, 10.4; p = 0.784), assessed by doubly labelled water, and -6.5% (90% CI -9.3, -3.7; p < 0.001), assessed by indirect calorimetry. CONCLUSION: Weight loss with cotadutide is primarily driven by reduced EI, with relatively small compensatory changes in EE. ; The study was funded by AstraZeneca and supported by the NIHR Cambridge Biomedical Research Centre. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://www.repository.cam.ac.uk/handle/1810/366303Test; https://doi.org/10.17863/CAM.107281Test |
| DOI: | 10.17863/CAM.107281 |
| الإتاحة: | https://doi.org/10.17863/CAM.107281Test https://www.repository.cam.ac.uk/handle/1810/366303Test |
| حقوق: | Attribution 4.0 International ; https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.EA5DFCF6 |
| قاعدة البيانات: | BASE |
| DOI: | 10.17863/CAM.107281 |
|---|